Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $35.67.
Several analysts have recently weighed in on CRBP shares. Oppenheimer restated an "outperform" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, November 11th. Mizuho reduced their price target on shares of Corbus Pharmaceuticals from $24.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, November 12th. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, September 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. Finally, Wall Street Zen cut Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th.
Get Our Latest Stock Report on Corbus Pharmaceuticals
Insiders Place Their Bets
In other Corbus Pharmaceuticals news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of Corbus Pharmaceuticals stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total value of $1,742,500.00. Following the transaction, the insider directly owned 1,919,971 shares in the company, valued at approximately $7,871,881.10. The trade was a 18.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.50% of the stock is currently owned by corporate insiders.
Institutional Trading of Corbus Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. purchased a new stake in shares of Corbus Pharmaceuticals in the 3rd quarter worth about $13,059,000. Marshall Wace LLP increased its holdings in Corbus Pharmaceuticals by 288.4% during the 3rd quarter. Marshall Wace LLP now owns 308,138 shares of the biopharmaceutical company's stock valued at $2,102,000 after acquiring an additional 228,807 shares in the last quarter. Orbimed Advisors LLC increased its holdings in Corbus Pharmaceuticals by 8.8% during the 1st quarter. Orbimed Advisors LLC now owns 1,737,287 shares of the biopharmaceutical company's stock valued at $16,313,000 after acquiring an additional 140,000 shares in the last quarter. Exome Asset Management LLC raised its position in Corbus Pharmaceuticals by 67.8% during the first quarter. Exome Asset Management LLC now owns 234,136 shares of the biopharmaceutical company's stock worth $2,199,000 after acquiring an additional 94,593 shares during the last quarter. Finally, Doliver Advisors LP acquired a new position in Corbus Pharmaceuticals during the third quarter worth about $518,000. Hedge funds and other institutional investors own 64.64% of the company's stock.
Corbus Pharmaceuticals Trading Down 9.0%
Shares of CRBP stock opened at $2.74 on Thursday. The firm has a fifty day moving average price of $5.24 and a 200 day moving average price of $8.26. The company has a market cap of $56.47 million, a P/E ratio of -0.45 and a beta of 2.80. Corbus Pharmaceuticals has a 12 month low of $2.62 and a 12 month high of $12.88.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.54). On average, equities analysts forecast that Corbus Pharmaceuticals will post -6.29 EPS for the current year.
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company based in Norwood, Massachusetts. It develops investigational medicines, with current research focused on cancer and obesity. Its oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, and CRB-601, an antibody targeting the αvβ8 integrin. The company is also developing CRB-913, an investigational drug candidate designed to act on the cannabinoid CB1 receptor for obesity treatment. These candidates are in development and are not approved medicines.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.